CHEST Guidelines-Correction-to-Funding-Support-in--International-Se

Correction-to-Funding-Support-in--International-Se

Pdf Summary

The document contains corrections regarding the funding and support details for two articles published in the journal "Chest" in 2020. <br /><br />The first correction pertains to the article titled "Characterization of Severe Asthma Worldwide: Data From the International Severe Asthma Registry" (Chest 2020; 157(4):790-804). The clarification states that the study was conducted by the Observational and Pragmatic Research Institute (OPRI) Pte Ltd and was partially funded by Optimum Patient Care Global and AstraZeneca Ltd. Contrary to previous statements, OPRI did not receive funding for its contribution. The online version of the article has been updated to reflect this correction.<br /><br />The second correction involves the article "International Severe Asthma Registry: Mission Statement" (Chest 2020; 157(4):805-814). Similar to the first article, the correction specifies that the study was conducted by OPRI and was partially funded by Optimum Patient Care Global and AstraZeneca Ltd, with no funding received by OPRI for its contribution. This correction has also been updated in the online version of the article.<br /><br />Both corrections serve to clarify misunderstandings about the funding and support contributions of OPRI and are officially documented as errata in the "Chest" journal.

Keywords

Chest journal

corrections

funding details

support details

Severe Asthma

Observational and Pragmatic Research Institute

Optimum Patient Care Global

AstraZeneca

errata

2020 articles